

**CONTACT - Media:**

Amsterdam +31.20.721.4488  
Lisbon +351.210.600.614

Brussels +32.2.620.15.50  
Paris +33.1.70.48.24.45

**CONTACT - Investor Relations:**

+33.1.70.48.24.17

**PHARMACEUTICALS SPECIALIST ADVICENNE LISTS ON EURONEXT PARIS****IPO raises €27 million; market capitalisation €112 million**


**Paris – 6 December 2017** – Advicenne, a pharmaceutical SME from the south of France at advanced stages of development, today celebrated its first day of trading on Euronext Paris. Funds raised through listing will help the company pursue clinical development of its leading product in Europe and the United States, and finance commercial growth in Europe.

Founded in Nîmes in 2007 by Dr Luc-André Granier, MD, and Caroline Roussel-Petit, respectively Chairman & CEO and Director of Operations, Advicenne develops therapeutic products for children and adults suffering from rare renal and neurological diseases. From the start, the company has been backed by leading venture capital investors including InnoBio (Bpifrance), IXO Private Equity, IRDI Soridec Gestion, Cemag Invest and MI Care, as well as private investors.

Advicenne (ticker code ADVIC) was listed through the admission to trading on 6 December 2017 of 8,002,696 shares making up the company's equity, including 2,007,718 new shares (after partial exercise of the extension clause and before exercise of the overallotment option), raising a total of €27 million euros, and may rise to €28.2 million euros in case of full-exercise of the over-allotment option.

The offering price was set at €14,03 per share and market capitalisation was around €112 million on the day of listing.

At the listing ceremony, the company's co-founder, Chairman & CEO Dr. Luc-André Granier, said: *"We are delighted to have completed our initial public offering on Euronext Paris, and to welcome new investors alongside our historical shareholders, who have confirmed their ongoing support for our team and our work. We would like to thank each and every one, both individuals and institutions, for placing their trust in Advicenne. This IPO represents a milestone in our strategy, and will enable us to pursue the clinical development of our lead product in both Europe and the United States, and lay the groundwork for its planned commercialisation in Europe in 2020."*



## CONTACTS -

### Euronext

Aichata Tandjigora (Paris): +33 1 70 48 24 43; [atandjigora@euronext.com](mailto:atandjigora@euronext.com)

### About Advicenne

Advicenne is a late-stage pharmaceutical company focusing on the development of pediatric- and adult-friendly therapeutics for the treatment of orphan renal and neurological diseases. The company's most advanced product is ADV7103, which has shown positive results in a pivotal Phase-III study in children and adults with distal Renal Tubular Acidosis (dRTA). ADV7103 is also being developed in a second indication for the treatment of Cystinuria, an inherited renal tubulopathy and is expected to enter into a pivotal Phase II/III clinical trial in 2018 in Europe. In addition to ADV7103, Advicenne has a portfolio of clinical and pre-clinical products targeting critical unmet needs in nephrology and neurology in collaboration with Key Opinion Leaders. The company was established in 2007 in Nimes (France). Since its inception, it has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care. Additional information about Advicenne is available through its website: [www.advicenne.com](http://www.advicenne.com)

### About Euronext

Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of the end September 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50® benchmark index and a strong and diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Euronext Growth™ (formerly Alternext) and Euronext Access™ (formerly Marché Libre).

### Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided "as is" without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at [www.euronext.com/terms-use](http://www.euronext.com/terms-use).

© 2017, Euronext N.V. - All rights reserved.